DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Nervous and Mental Disease

• Publication date

  2002-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00005053-200209000-00002PMID 12357091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Obesity as a risk factor for antipsychotic noncompliance.

  2004cited by this paper
• Between the lines: navigating the uncharted territory of industry-sponsored research.

  2002cited by this paper
• Drug firms hype disease as sales ploy, industry chief claims

  2002cited by this paper
• From clinical trial to prescription.

  2002cited by this paper
• Randomized controlled trials in schizophrenia: a critical perspective on the literature

  2002cited by this paper
• Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

  2001cited by this paper
• Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

  2001cited by this paper
• Evaluating Clinical Trial Data From Schizophrenia Research

  2001cited by this paper
• Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study.

  2001influential reference
• Sponsorship, authorship, and accountability.

  2001cited by this paper
• Antipsychotic-induced weight gain: a review of the literature.

  2001cited by this paper
• Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.

  2001cited by this paper
• Is academic medicine for sale?

  2001cited by this paper
• Maintaining the integrity of the clinical evidence base.

  2001cited by this paper
• Olanzapine treatment for patients with schizophrenia and substance abuse.

  2001cited by this paper
• Medicine in the noise age: What can we believe?

  2001cited by this paper
• Sponsorship, authorship, and accountability.

  2001cited by this paper
• Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

  2000influential reference
• The industrialization of clinical research.

  2000cited by this paper
• Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.

  2000cited by this paper
• The pharmaceutical industry--to whom is it accountable?

  2000cited by this paper
• Anxiety and mood disorders

  2000cited by this paper
• The pharmaceutical industry--to whom is it accountable?

  2000cited by this paper
• The pharmaceutical industry--to whom is it accountable?

  2000cited by this paper
• Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia

  2000cited by this paper
• Electrodiagnostic studies in ulnar neuropathy at the elbow.

  2000influential reference
• Effectiveness of Treatments for Nocturnal Enuresis in a Heterogeneous Population

  2000cited by this paper
• Uneasy alliance--clinical investigators and the pharmaceutical industry.

  2000cited by this paper
• Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment.

  2000cited by this paper
• Increased Rate of Trazodone Prescribing with Bupropion and Selective Serotonin-Reuptake Inhibitors versus Tricyclic Antidepressants

  2000influential reference
• Claims of Equivalence in Medical Research: Are They Supported by the Evidence?

  2000cited by this paper
• How companies stall generics and keep themselves healthy.

  2000cited by this paper
• Is academic medicine for sale?

  2000cited by this paper
• Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial.

  2000cited by this paper
• Publication bias and the integrity of psychiatry research

  2000cited by this paper
• Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

  2000cited by this paper
• Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.

  1999cited by this paper
• Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.

  1999cited by this paper
• A dose-outcome analysis of risperidone.

  1999cited by this paper
• A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.

  1999influential reference
• Partial response to antipsychotic treatment: the patient with enduring symptoms.

  1999cited by this paper
• A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.

  1999cited by this paper
• Fair conduct and fair reporting of clinical trials.

  1999cited by this paper
• Inadequate prescription-drug coverage for Medicare enrollees--a call to action.

  1999cited by this paper
• Changes in adverse events reported by patients during 6 months of fluoxetine therapy.

  1999cited by this paper
• Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

  1999cited by this paper
• Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia ∗

  1999cited by this paper
• Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.

  1999influential reference
• Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.

  1999cited by this paper
• Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

  1999cited by this paper
• Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.

  1999cited by this paper
• Efficacy and tolerability of ‘Seroquel’ compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment

  1999cited by this paper
• Venlafaxine versus fluoxetine in the treatment of depressed patients with concomitant anxiety

  1999cited by this paper
• Quetiapine and risperidone in outpatients with psychotic disorders: Results of the QUEST trial

  1999cited by this paper
• Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone

  1999cited by this paper
• A doctor's drug studies turn into fraud.

  1999cited by this paper
• Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment

  1999influential reference
• Optimal Haloperidol Dosage in First-Episode Psychosis

  1999cited by this paper
• Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

  1999cited by this paper
• Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.

  1999cited by this paper
• Drug trials hide conflicts for doctors.

  1999cited by this paper
• Mood Stabilizers and Mood Swings: In Search of a Definition

  1999cited by this paper
• A combined analysis of double‐blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms

  1999cited by this paper
• Manufacturer support and outcome.

  1999cited by this paper
• Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

  1999cited by this paper
• To what extent should papers submitted from drug companies be published in medical journals?

  1999cited by this paper
• Risperidone in treatment-refractory schizophrenia.

  1999cited by this paper
• CORPORATE COLLABORATIONS : SCIENTISTS CAN FACE PUBLISHING CONSTRAINTS

  1999cited by this paper
• Newer antipsychotics in treatment-resistant schizophrenia.

  1999cited by this paper
• A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

  1999cited by this paper
• Antipsychotic-induced weight gain: a comprehensive research synthesis.

  1999cited by this paper
• Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals.

  1998cited by this paper
• American health care systems and depression: the past, present, and the future.

  1998cited by this paper
• Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.

  1998cited by this paper
• FDA's Rx for keeping educational programs free of industry bias.

  1998cited by this paper
• Globalization in the pharmaceutical industry, Part I.

  1998cited by this paper
• Private sector becoming the key to research funding in Canada.

  1998cited by this paper
• Legal issues surrounding privately funded research cause furore in Toronto.

  1998cited by this paper
• Constraints of interest: lessons at the Hospital for Sick Children.

  1998cited by this paper
• Industry affiliations and scientific conclusions.

  1998cited by this paper
• The Escalating Pharmaceutical Company Wars: Where is an Academic to Hide?

  1998cited by this paper
• Scientific Journals and Their Authors’ Financial Interests: A Pilot Study

  1998cited by this paper
• Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

  1998cited by this paper
• Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

  1998cited by this paper
• Globalization in the Pharmaceutical Industry, Part I

  1998cited by this paper
• Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

  1998cited by this paper
• Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

  1998cited by this paper
• Industry affiliations and scientific conclusions.

  1998cited by this paper
• Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

  1997influential reference
• Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators.

  1997cited by this paper
• Thyroid storm.

  1997influential reference
• Are me-too drugs justified?

  1997cited by this paper
• A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.

  1997cited by this paper
• Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

  1997influential reference
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997cited by this paper
• SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

  1997cited by this paper
• Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

  1997influential reference
• Putting trials on trial--the costs and consequences of small trials in depression: a systematic review of methodology.

  1997cited by this paper
• A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.

  1997cited by this paper
• Extrapyramidal symptoms in patients treated with risperidone.

  1997cited by this paper

• Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.

  2026cites this paper
• Core GRADE 5: rating certainty of evidence—assessing indirectness

  2025cites this paper
• PHARMACEUTICAL MARKETING AND PUBLIC HEALTH: CONSCIOUS CONSUMPTION OR MANIPULATION?

  2025cites this paper
• The New Modern Medicine

  2025cites this paper
• A Critical Review of Pharmaceutical Industry Fraudulent Practices

  2025cites this paper
• Industry Funding by Itself is Not a Reason for Rating Down Studies for Risk of Bias

  2024cites this paper
• Strengthening the Reporting of Observational Studies in Epidemiology(STROBE): 국문판 설명문서

  2024cites this paper
• Commercial funding and estimated intervention effects in randomized clinical trials: Systematic review of meta‐epidemiological studies

  2022cites this paper
• Повышение качества отчетов о наблюдательных исследованиях в эпидемиологии (STROBE): разъяснения и уточнения

  2021cites this paper
• Objectivity for the research worker

  2021cites this paper
• [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration].

  2021cites this paper
• Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression

  2020cites this paper
• Medición de la concordancia en la elección de antidepresivos entre psiquiatras costarricenses que no aplican y sí aplican el Algoritmo de Razonamiento Psicofarmacológico

  2019cites this paper
• pushing children into suicide with happy pills

  2019cites this paper
• Considering bias and conflicts of interest among the included studies

  2019cites this paper
• Randomized clinical trials with run-in periods: frequency, characteristics and reporting

  2019cites this paper
• Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events.

  2019cites this paper
• Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials

  2019cites this paper
• Collecting data

  2019cites this paper
• Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study

  2018cites this paper
• Industry sponsorship and research outcome: systematic review with meta-analysis

  2018cites this paper
• Effect of desensitizing toothpastes on dentine hypersensitivity: A systematic review and meta-analysis.

  2018cites this paper
• The promise and perils of industry-funded science

  2018cites this paper
• Industry sponsorship and research outcome.

  2017cites this paper
• The popularity of antidepressant Is the Efficacy of “ Antidepressant ” Medications Overrated ?

  2017cites this paper
• Consent and confidentiality in the light of recent demands for data sharing

  2017cites this paper
• Is the Efficacy of “Antidepressant” Medications Overrated?

  2017cites this paper
• Marketing trials, marketing tricks — how to spot them and how to stop them

  2017cites this paper
• Comparison of rates of nausea side effects for prescription medications from an online patient community versus medication labels: an exploratory analysis

  2017cites this paper
• Análisis de la estética y la remodelación ósea en implantes post-extracción rehabilitados de manera inmediata con coronas unitarias atornilladas. Estudio clínico retrospectivo a 5 años

  2017cites this paper
• Explanation and Elaboration Document for the STROBE‐Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology—Veterinary Extension

  2016cites this paper
• elaboration document for the STROBE-Vet statement strengthening the reporting of observational studies in epidemiology-veterinary extension

  2016cites this paper
• Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care.

  2016cites this paper
• Big Pharma Entanglement with Biomedical Science

  2016cites this paper
• The Effect of Calcium Sodium Phosphosilicate on Dentin Hypersensitivity: A Systematic Review and Meta-Analysis

  2015cites this paper
• Do We Need a Science of Science

  2015cites this paper
• Clinical Trials of New Drug Products: What Gets Compared to Whom

  2015cites this paper
• Análisis crítico de ensayos clínicos aleatorizados: Riesgo de sesgo Critical analysis of randomized clinical trials: The risk of bias

  2015cites this paper
• The Problem of Intransigently Biased Agents

  2015cites this paper
• Clinical Trials Abroad: The Marketable Ethics, Weak Protections and Vulnerable Subjects of EU Law

  2014cites this paper
• An overview of the current status of clinical trials on endometriosis: issues and concerns.

  2014cites this paper
• Bias related to funding source in statin trials

  2014cites this paper
• THE LIMITED EFFECTIVENESS OF PRESTIGE AS AN INTERVENTION ON THE HEALTH OF MEDICAL JOURNAL PUBLICATIONS

  2013cites this paper
• Publication Bias, with a Focus on Psychiatry: Causes and Solutions

  2013cites this paper
• Comparator bias: why comparisons must address genuine uncertainties

  2013cites this paper
• Why negative meta-analyses may be false?

  2013cites this paper
• Conflict of Interest in the Assessment of Botulinum Toxin A Injections in Patients With Cerebral Palsy: A Systematic Review

  2013cites this paper
• Why the Cochrane risk of bias tool should include funding source as a standard item.

  2013cites this paper
• Bias , with a Focus on Psychiatry : Causes and Solutions

  2013cites this paper
• Conflicts of interest in biomedical publishing

  2012influential citation
• Promoting transparency in pharmaceutical industry-sponsored research.

  2012cites this paper
• Industry sponsorship and research outcome.

  2012cites this paper
• DSM-5 Changes on the Horizon: Substance Use Disorders

  2012cites this paper
• PHARMACEUTICAL-INDUSTRY SPONSORED RESEARCH: PROMOTING TRANSPARENCY

  2012cites this paper
• From treatment adherence to advanced shared decision making: new professional strategies and attitudes in mental health care.

  2011cites this paper
• The effect of funding source on outcome reporting among drug trials.

  2011cites this paper
• Modified versus standard intention-to-treat reporting: Are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study

  2011cites this paper
• The Effect of Funding Source on Outcome Reporting Among Drug Trials

  2011cites this paper
• Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications

  2011cites this paper
• 1 ROBUSTNESS OF RESULTS AND CONCLUSIONS IN SYSTEMATIC REVIEWS , TRIALS AND

  2011cites this paper
• Why we need easy access to all data from all clinical trials and how to accomplish it

  2011cites this paper
• Can Online Consumers Contribute to Drug Knowledge? A Mixed-Methods Comparison of Consumer-Generated and Professionally Controlled Psychotropic Medication Information on the Internet

  2011cites this paper
• Clinical Trial Design for Chronic Pain Treatments

  2010cites this paper
• The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

  2010cites this paper
• Understanding the assessment of psychotropic drug harms in clinical trials to improve social workers' role in medication monitoring.

  2010cites this paper
• Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

  2010cites this paper
• Scientific uncertainty and the creation of resuscitation guidelines

  2010cites this paper
• Medical Education Meets Pharma: Moving Ahead

  2010cites this paper
• Strengthening conflict-of-interest policies in medicine.

  2010cites this paper
• Ethics and EBM: acknowledging bias, accepting difference and embracing politics.

  2010cites this paper
• Unbalanced reporting of benefits and harms in abstracts on rofecoxib

  2010cites this paper
• Psychiatric drugs and common factors: An evaluation of risks and benefits for clinical practice.

  2010cites this paper
• Evidence-Based Medicine Evidence-Based Medicine , Systematic Reviews , and Guidelines in Interventional Pain Management : Part 4 : Observational Studies

  2010cites this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cites this paper
• To ban or not to ban: direct-to-consumer advertising and human rights analysis

  2010cites this paper
• Building comparative efficacy and tolerability into the FDA approval process.

  2010cites this paper
• How should a clinician interpret results of randomized controlled trials? Interpretation of randomized controlled trials

  2010cites this paper
• Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine

  2010cites this paper
• Appraising Evidence for Intervention Effectiveness in Early Psychosis: Conceptual Framework and Review of Evaluation Approaches

  2010cites this paper
• Association Between Research Sponsorship and Study Outcome in Plastic Surgery Literature

  2009cites this paper
• Why Reading the Title Isn't Good Enough: An Evaluation of the 4S Approach to Evidence-Based Medicine

  2009cites this paper
• How do disclosure policies fail? Let us count the ways

  2009cites this paper
• Better Regulation of Industry-Sponsored Clinical Trials is Long Overdue

  2009cites this paper
• Why Diagnosis of ADHD has Increased so Rapidly in the West: A Cultural Perspective

  2009cites this paper
• `Consumers are Patients!' Shared Decision-making and Treatment Non-compliance as Business Opportunity

  2009cites this paper
• Relationships Between Drug Company Representatives and Medical Students: Medical School Policies and Attitudes of Student Affairs Deans and Third-Year Medical Students

  2009cites this paper
• Financial and non-financial conflicts of interests in psychiatry

  2009cites this paper
• Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? Yes

  2009cites this paper
• The Rigor of Research Design and “Forensic” Publications in Neuropsychological Research

  2009cites this paper
• Determinanten für den Ein- und Ausschluss von Patienten bei Phase III- und IV-Studien an einer psychiatrisch-psychotherapeutischen Versorgungsklinik

  2009cites this paper
• Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.

  2008cites this paper
• Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues †

  2008cites this paper
• Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee.

  2008cites this paper
• Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation

  2008cites this paper
• Clinical perspectives in drug safety and adverse drug reactions

  2008cites this paper
• World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

  2008cites this paper
• [Financial conflict of interest in clinical psychiatry studies: a review].

  2008influential citation
• Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.

  2008cites this paper
• Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?

  2008cites this paper
• Cleaning Up Evidence‐Based Psychopharmacology

  2008cites this paper